Stock CALC CALCIMEDICA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News CalciMedica, Inc.

Equities

CALC

US38942Q2021

End-of-day quote Nasdaq
Other stock markets
 18:00:00 2024-05-06 EDT 		5-day change 1st Jan Change
5.52 USD -2.13% Intraday chart for CalciMedica, Inc. -3.66% +93.01%
04-24 Calcimedica Inc. Announces Last Patient Enrolled in Phase 2B Carpo Trial of Auxora? in Acute Pancreatitis CI
04-01 Top Premarket Decliners MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora in Acute Pancreatitis
AQ
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis
PR
Calcimedica Inc. Announces Last Patient Enrolled in Phase 2B Carpo Trial of Auxora? in Acute Pancreatitis
CI
Top Premarket Decliners
MT
CalciMedica : Material Event - Form 8-K
PU
CalciMedica, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
PR
CalciMedica Inc. Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International Acute Kidney Injury At the 29th International Aki & CRRT Conference
CI
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI and CRRT Conference
AQ
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
PR
JonesTrading Initiates CalciMedica With Buy Rating, Price Target is $22
MT
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora for the Treatment of Severe Acute Kidney Injury
AQ
CalciMedica Gets FDA Nod for Phase 2 Trial of Acute Kidney Injury With Respiratory Failure Treatment
MT
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury
PR
Calcimedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora? for the Treatment of Severe Acute Kidney Injury
CI
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PR
CalciMedica, Inc. announced that it has received $20.252897 million in funding
CI
HC Wainwright Starts Coverage on CalciMedica with Buy Rating, $20 Price Target
MT
Calcimedica Insider Bought Shares Worth $2,515,080, According to a Recent SEC Filing
MT
CalciMedica Secures $55 Million Funding Deal With Investors; Shares Gain
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CALC Stock
  4. News CalciMedica, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW